$CYTKNASDAQ:CYTK this about to bust :) look at that low volume and consolidation building. Get ready for these Small CAPS. LONG DONG STYLE
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.699 CHF
−535.41 M CHF
16.78 M CHF
116.73 M
About Cytokinetics, Incorporated
Sector
Industry
CEO
Robert I. Blum
Website
Headquarters
South San Francisco
Founded
1997
FIGI
BBG00LVD6PZ0
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
Why Now is the Time to Buy Cytokinetics ($CYTK) Stock
In the dynamic landscape of the stock market, investors are constantly on the lookout for hidden gems that offer promising returns. Cytokinetics ( NASDAQ:CYTK ), a biopharmaceutical company dedicated to developing muscle activators, is emerging as a compelling investment opportunity. This Idea delv
CYTK +20%Here we see a breakout the ascending channel, which indicates an acceleration of the upward movement.
CYTK - Leader in the Biotech industryVCP setup. Trend line breakout. Entry on FED day!
Biotech industry made a double bottom with confirmation pivot reversal (see IBB & XBI ETF).
New Highs & Levels For CYTKCYTK put in a fresh high today which was rejected HARD almost immediately after. This came after the company announced positive topline results from 2 cohorts in its REDWOOD-HCM Phase 2 clinical trial of CK-3773274 (CK-274). This is the company’s investigational treatment targeting hypertrophic car
Cytokinetics $CYTK - investment idea 💡 This entry and SL is based on my technical analysis only.
Do your research and trade on your own risk!
CYTK, Broadening Wedge Descending (bearish) I found this pattern at tickeron website with the following data:
STATUS = Confirmed
CURRENT CONFIDENCE = 82%
TARGET (EXIT) PRICE = 14.29 USD
BREAKOUT (ENTRY) PRICE = 15.34 USD
DISTANCE TO TARGET PRICE = 8.46%
EMERGED ON = Oct 28, 12:00 PM (EDT)
CONFIRMED ON = Oct 28, 03:56 PM (EDT)
WITH CONFIDENCE
CYTK, Pennant (bullish pattern)I found this pattern at tickeron website with the following data:
STATUS = Confirmed
CURRENT CONFIDENCE = 77%
TARGET (EXIT) PRICE = 18.60 USD
BREAKOUT (ENTRY) PRICE = 16.75 USD
DISTANCE TO TARGET PRICE = 14.39%
EMERGED ON = Oct 19, 12:00 PM (EDT)
CONFIRMED ON = Oct 19, 11:59 AM (EDT)
WITH CONFIDENCE
CYTK, MACD Histogram just turned positiveThis is a Bullish indicator signaling CYTK's price could rise from here. Traders may explore going long the stock or buying call options. Tickeron A.I. dvisor identified 44 similar cases where CYTK's MACD histogram became positive, and 42 of them led to successful outcomes. Odds of Success: 90%. Cur
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
CYTK5615147
Cytokinetics, Incorporated 3.5% 01-JUL-2027Yield to maturity
−0.14%
Maturity date
Jul 1, 2027
CYTK4910847
Cytokinetics, Incorporated 4.0% 15-NOV-2026Yield to maturity
−22.31%
Maturity date
Nov 15, 2026
See all KK3A bonds
Related stocks
Frequently Asked Questions
The current price of KK3A is 28.544 CHF — it has decreased by −39.25% in the past 24 hours. Watch CYTOKINETICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange CYTOKINETICS INC stocks are traded under the ticker KK3A.
KK3A stock has fallen by −39.25% compared to the previous week, the month change is a −39.25% fall, over the last year CYTOKINETICS INC has showed a −49.64% decrease.
We've gathered analysts' opinions on CYTOKINETICS INC future price: according to them, KK3A price has a max estimate of 98.71 CHF and a min estimate of 33.73 CHF. Watch KK3A chart and read a more detailed CYTOKINETICS INC stock forecast: see what analysts think of CYTOKINETICS INC and suggest that you do with its stocks.
KK3A reached its all-time high on Jan 10, 2024 with the price of 85.736 CHF, and its all-time low was 29.520 CHF and was reached on Nov 13, 2023. View more price dynamics on KK3A chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
KK3A stock is 64.61% volatile and has beta coefficient of 0.99. Track CYTOKINETICS INC stock price on the chart and check out the list of the most volatile stocks — is CYTOKINETICS INC there?
Today CYTOKINETICS INC has the market capitalization of 3.33 B, it has increased by 1.86% over the last week.
Yes, you can track CYTOKINETICS INC financials in yearly and quarterly reports right on TradingView.
CYTOKINETICS INC is going to release the next earnings report on Jul 31, 2025. Keep track of upcoming events with our Earnings Calendar.
KK3A earnings for the last quarter are −1.20 CHF per share, whereas the estimation was −1.21 CHF resulting in a 0.68% surprise. The estimated earnings for the next quarter are −1.15 CHF per share. See more details about CYTOKINETICS INC earnings.
CYTOKINETICS INC revenue for the last quarter amounts to 1.42 M CHF, despite the estimated figure of 3.03 M CHF. In the next quarter, revenue is expected to reach 1.63 M CHF.
KK3A net income for the last quarter is −142.86 M CHF, while the quarter before that showed −136.25 M CHF of net income which accounts for −4.85% change. Track more CYTOKINETICS INC financial stats to get the full picture.
No, KK3A doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 15, 2025, the company has 498 employees. See our rating of the largest employees — is CYTOKINETICS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CYTOKINETICS INC EBITDA is −492.32 M CHF, and current EBITDA margin is −2.85 K%. See more stats in CYTOKINETICS INC financial statements.
Like other stocks, KK3A shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CYTOKINETICS INC stock right from TradingView charts — choose your broker and connect to your account.